Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Apr 9;20(4):e0320804.
doi: 10.1371/journal.pone.0320804. eCollection 2025.

Osteopontin, kidney injury molecule-1, and fetuin-A as prognostic markers of end-stage renal disease: A systematic review and meta-analysis

Yongki Welliam  1 , Bendix Samarta Witarto  1 , Visuddho Visuddho  1 , Citrawati Dyah Kencono Wungu  2   3 , Raden Mohammad Budiarto  4 , Hendri Susilo  4   5 , Chaq El Chaq Zamzam Multazam  6
Affiliations
Meta-Analysis

Osteopontin, kidney injury molecule-1, and fetuin-A as prognostic markers of end-stage renal disease: A systematic review and meta-analysis

Yongki Welliam et al. PLoS One. .

Abstract

Background: The global prevalence of chronic kidney disease (CKD) as a major renal disease is increasing rapidly. The progression of CKD may lead to end-stage renal disease (ESRD). Current diagnostic and prognostic methods still have some limitations. This study aims to evaluate the potential and predictive ability of Osteopontin (OPN), Kidney injury molecule-1 (KIM-1), and Fetuin-A on the incidence of ESRD in CKD patients.

Methods: A systematic review and meta-analysis were carried out based on the PRISMA guideline on registered databases for studies published up to December 21, 2023. The concentrations of each marker were then reported in pooled standardized mean difference (SMD) and hazard ratio (HR). Subgroup analysis was performed based on age, location, and KIM-1 specimen.

Results: We included 21 studies involving 15,983 patients. Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59-9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50-2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 - -0.26, p = 0.01) were significant in CKD patients with ESRD. Chronic kidney disease patients with increased KIM-1 levels showed 1.13 times increased risk of ESRD (HR = 1.13, 95% CI = 1.10-1.17, p <0.0001). Subgroup analysis showed that increased KIM-1 in urine or blood was strongly associated with ESRD, and decreased Fetuin-A levels in Asians had a significant association with the incidence of ESRD.

Conclusion: Osteopontin, KIM-1, and Fetuin-A significantly reflect ESRD in CKD patients, making them potential prognostic indicators.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA Flow Chart 2020.
Fig 2
Fig 2. Forest plot for the pooled SMD in ESRD and non-ESRD among CKD patients.
(A) OPN; (B) KIM-1; and (C) Fetuin-A.
Fig 3
Fig 3. Forest plot for the pooled HR in ESRD and non-ESRD among CKD patients.
(A) OPN and (B) KIM-1.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al.. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1–87. - PubMed
    1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3 - DOI - PMC - PubMed
    1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048–50. Available from: doi: 10.1016/j.kint.2019.07.012 - DOI - PubMed
    1. Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J. Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. Nephron. 2024;148(2):113–23. - PMC - PubMed
    1. Kidey Disease. Improving Global Outcomes (KDIGO). Nomenclature for Kidney Function and Disease. A KDIGO Consensus Conference on Nomenclature. 2019

MeSH terms